TrueRelief

Executive Summary

TrueRelief is a Boston-based digital health company founded in 2019, developing a non-invasive, non-opioid neuromodulation device for pain management. Its FDA-cleared technology targets acute and chronic pain, particularly in post-surgical settings, aiming to reduce opioid usage. The device is administered by healthcare professionals in clinical environments, addressing the critical need for safe, effective pain relief amid the opioid crisis. With a focus on evidence-based outcomes, TrueRelief is positioned to capture a significant share of the pain management market, which is shifting toward non-pharmacological solutions. The company's early traction and regulatory clearance provide a foundation for scalable growth, though detailed financials and commercial milestones remain undisclosed as a private entity.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance for Expanded Indications (e.g., Chronic Pain)70% success
• Q4 2026Series A Financing Round60% success
• Q2 2026Strategic Partnership with Major Hospital Network75% success